Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;58(3):1693-8.
doi: 10.1128/AAC.02210-13. Epub 2013 Dec 30.

In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae

Giorgio Piccinelli  1 , Prabhavathi Fernandes, Carlo Bonfanti, Francesca Caccuri, Arnaldo Caruso, Maria Antonia De Francesco
Affiliations

In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae

Giorgio Piccinelli et al. Antimicrob Agents Chemother. 2014.

Erratum in

Abstract

The in vitro antibacterial activity of solithromycin (CEM-101) against macrolide-resistant isolates (n=62) of Streptococcus agalactiae (group B streptococcus [GBS]) was determined. Phenotypic characterization of macrolide-resistant strains was performed by double-disc diffusion testing. A multiplex PCR was used to identify the erm(B), erm(TR), and mef(A/E) genes, capsular genotypes, and alpha-like (Alp) protein genes from the GBS strains. Determination of MIC was carried out using the microdilution broth method. The Etest method was used for penicillin, azithromycin, clarithromycin, and erythromycin. Solithromycin had a MIC50 of ≤0.008 μg/ml and a MIC90 of 0.015 μg/ml against macrolide-susceptible S. agalactiae. These MICs were lower than those displayed by penicillin (MIC50 of 0.032 μg/ml and MIC90 of 0.047 μg/ml), the antibiotic agent of choice for prophylaxis and treatment of GBS infections. Against macrolide-resistant S. agalactiae, solithromycin had a MIC50 of 0.03 μg/ml and a MIC90 of 0.125 μg/ml. Against erm(B) strains, solithromycin had a MIC50 of 0.03 μg/ml and a MIC90 of 0.06 μg/ml, while against mef(A) strains, it had a MIC50 of 0.03 μg/ml and a MIC90 of 0.125 μg/ml. Most erythromycin-resistant GBS strains were of serotype V (64.5%) and associated significantly with alp2-3. Moreover, a statistically significant association was observed between the constitutive macrolide-lincosamide-streptogramin B resistance (cMLSB) phenotype and the erm(B) gene-carrying strains, the alp2-3 gene and the M phenotype, and the mef(A/E) gene and epsilon. Overall, our results show that solithromycin had lower or similar MICs than penicillin and potent activity against macrolide-resistant strains independent of their genotype or phenotype, representing a valid therapeutic alternative where β-lactams cannot be used.

PubMed Disclaimer

Figures

FIG 1
FIG 1
MIC distribution of penicillin (a) and solithromycin (b) for the different phenotypes of macrolide-resistant Streptococcus agalactiae strains.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baker CJ. 2000. Group B streptococcal infections, p 222–237 In Stevens DL, Kaplan EL. (ed), Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. Oxford University Press, New York, NY
    1. Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, Wenger JD, Schuchat A. 1995. Risk factors for group B streptococcal disease in adults. Ann. Intern. Med. 123:415–420. 10.7326/0003-4819-123-6-199509150-00003 - DOI - PubMed
    1. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni Tl, Tighe H, O'Connell LA, Cafferkey M, Verlander NQ, Nicoll A, McCartney AC, PHLS GBS Working Group. 2004Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363:292–294. 10.1016/S0140-6736(03)15389-5 - DOI - PubMed
    1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. 2002. Changes in pathogens causing early-onset sepsis in very low-birth weight infants. N. Engl. J. Med. 347:240–247. 10.1056/NEJMoa012657 - DOI - PubMed
    1. Federal Register 2013. Establishing a list of qualifying pathogens under the Food And Drug Administration Safety and Innovation Act. Proposed rule. Fed. Regist. 78:35155–35173 - PubMed

Publication types

MeSH terms

LinkOut - more resources